Literature DB >> 34297242

Sex differences in associations between birth characteristics and childhood cancers: a five-state registry-linkage study.

Lindsay A Williams1,2,3, Jeannette Sample4, Colleen C McLaughlin5, Beth A Mueller6,7, Eric J Chow6, Susan E Carozza8, Peggy Reynolds9, Logan G Spector4,10,11.   

Abstract

BACKGROUND: There is a well-recognized male excess in childhood cancer incidence; however, it is unclear whether there is etiologic heterogeneity by sex when defined by epidemiologic risk factors.
METHODS: Using a 5-state registry-linkage study (cases n = 16,411; controls n = 69,816), we estimated sex-stratified odds ratios (OR) and 95% confidence intervals (95% CI) between birth and demographic characteristics for 16 pediatric cancers. Evidence of statistical interaction (p-interaction < 0.01) by sex was evaluated for each characteristic in each cancer.
RESULTS: Males comprised > 50% of cases for all cancers, except Wilms tumor (49.6%). Sex interacted with a number of risk factors (all p-interaction < 0.01) including gestational age for ALL (female, 40 vs. 37-39 weeks OR: 0.84, 95% CI 0.73-0.97) and ependymoma (female, 40 vs. 37-39 OR: 1.78, 95% CI 1.14-2.79; female, ≥ 41 OR: 2.01. 95% CI 1.29-3.14), birth order for AML (female,  ≥ 3rd vs. 1st OR: 1.39, 95% CI 1.01-1.92), maternal education for Hodgkin lymphoma (male, any college vs. < high school[HS] OR: 1.47, 95% CI 1.03-2.09) and Wilms tumor (female, any college vs. HS OR: 0.74, 95% CI 0.59-0.93), maternal race/ethnicity for neuroblastoma (male, black vs. white OR: 2.21, 95% CI 1.21-4.03; male, Hispanic vs. white OR: 1.86, 95% CI 1.26-2.75; female, Asian/Pacific Islander vs. white OR: 0.28, 95% CI 0.12-0.69), and paternal age (years) for hepatoblastoma in males (< 24 vs. 25-29 OR: 2.17, 95% CI 1.13-4.19; ≥ 35 vs. 25-29 OR: 2.44, 95% CI 1.28-4.64).
CONCLUSIONS: These findings suggest etiologic heterogeneity by sex for childhood cancers for gestational age, maternal education, and race/ethnicity and paternal age.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Etiologic heterogeneity; Pediatric cancer; Registry-based study; Sex differences

Year:  2021        PMID: 34297242     DOI: 10.1007/s10552-021-01479-1

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  27 in total

1.  SEX DIFFERENCES IN SUSCEPTIBILITY TO INFECTIONS.

Authors:  T C WASHBURN; D N MEDEARIS; B CHILDS
Journal:  Pediatrics       Date:  1965-01       Impact factor: 7.124

Review 2.  X-chromosome genetics and human cancer.

Authors:  Alain Spatz; Christophe Borg; Jean Feunteun
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

3.  Parental age and risk of childhood cancer: a pooled analysis.

Authors:  Kimberly J Johnson; Susan E Carozza; Eric J Chow; Erin E Fox; Scott Horel; Colleen C McLaughlin; Beth A Mueller; Susan E Puumala; Peggy Reynolds; Julie Von Behren; Logan G Spector
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

4.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

Review 5.  Genetic and nongenetic risk factors for childhood cancer.

Authors:  Logan G Spector; Nathan Pankratz; Erin L Marcotte
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

Review 6.  Sex differences in immune responses.

Authors:  Sabra L Klein; Katie L Flanagan
Journal:  Nat Rev Immunol       Date:  2016-08-22       Impact factor: 53.106

Review 7.  The X chromosome in immune functions: when a chromosome makes the difference.

Authors:  Claude Libert; Lien Dejager; Iris Pinheiro
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

8.  Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features.

Authors:  Anna Hoppmann; Adele P Williams; Aubrey Coleman; Clay Tynes; Grant R Williams; Elizabeth Mroczek-Musulman; Jamie Aye; Kimberly F Whelan; Michael R Clay; Sarangarajan Ranganathan; Elizabeth A Beierle
Journal:  Pediatr Blood Cancer       Date:  2019-11-13       Impact factor: 3.167

9.  Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis.

Authors:  Eric J Chow; Susan E Puumala; Beth A Mueller; Susan E Carozza; Erin E Fox; Scott Horel; Kimberly J Johnson; Colleen C McLaughlin; Peggy Reynolds; Julie Von Behren; Logan G Spector
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

10.  Childhood cancer among twins and higher order multiples.

Authors:  Susan E Puumala; Susan E Carozza; Eric J Chow; Erin E Fox; Scott Horel; Kimberly J Johnson; Colleen McLaughlin; Beth A Mueller; Peggy Reynolds; Julie Von Behren; Logan G Spector
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.